E
Amylyx Pharmaceuticals, Inc. AMLX
$14.05 $0.161.15% NASDAQ
Recommendation
Prev Close
$13.89
Volume
7
Avg Vol (90D)
1,818,744
Market Cap
$1.48B
Dividend & Yield
--
52-Week Range
$2.60 - $16.96
P/E (TTM)
--
EPS (TTM)
-$2.50
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
10/30/2025 - GuruFocus
Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Five Below, Inc. (NASDAQ: FIVE); Humana Inc. (NYSE: HUM); and Treace Medical Concepts (NASDAQ: TMCI): Grabar Law Office Investigates Claims on Your Behalf
10/30/2025 - Globe Newswire
Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
10/30/2025 - Business Wire
Q3 Earnings Estimate for AMLX Issued By Lifesci Capital
10/30/2025 - MarketBeat
Amylyx Pharmaceuticals (AMLX) Is Down 6.3% After Lawsuit Over Relyvrio Disclosures Advances What's Changed
10/28/2025 - Simply Wall St
Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Rating Upgraded by Lifesci Capital
10/28/2025 - MarketBeat
Amylyx Pharmaceuticals (AMLX, $14.23) entered Uptrend as Momentum indicator ascends above 0 level on Oct 27, 2025
10/28/2025 - Tickeron - Stocks
Amylyx Pharmaceuticals Advances Phase 3 Study for Post-Bariatric Hypoglycemia Treatment
10/27/2025 - TipRanks Financial Blog
Amylyx Pharmaceuticals Advances ALS Treatment with Promising Study Update
10/27/2025 - TipRanks Financial Blog
Halper Sadeh LLC Encourages Amylyx Pharmaceuticals, Inc. ...
10/27/2025 - GuruFocus
Halper Sadeh LLC Encourages Amylyx Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights
10/27/2025 - Business Wire
Amylyx Pharmaceuticals (NASDAQ:AMLX) Given Sell (E+) Rating at Weiss Ratings
10/25/2025 - MarketBeat
Assessing Amylyx Pharmaceuticals (AMLX) Valuation Following a 74% Three-Month Share Price Surge
10/25/2025 - Simply Wall St
What Makes Amylyx Pharmaceuticals, Inc. (AMLX) a Strong Momentum Stock: Buy Now?
10/24/2025 - Zacks Investment Research
Wall Street Analysts See a 29.28% Upside in Amylyx Pharmaceuticals (AMLX): Can the Stock Really Move This High?
10/24/2025 - Zacks Investment Research
Has Amylyx Pharmaceuticals (AMLX) Outpaced Other Medical Stocks This Year?
10/24/2025 - Zacks Investment Research
Billionaire Steve Cohen's 10 Small-Cap Stocks Picks with Huge Upside Potential
10/24/2025 - Insider Monkey
Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Baxter International Inc. (NYSE: BAX); Five Below, Inc. (NASDAQ: FIVE); and Humana Inc. (NYSE: HUM): Grabar Law Office Investigates Claims on Your Behalf
10/23/2025 - Globe Newswire
Amylyx Pharmaceuticals (AMLX, $14.82) Aroon Indicator entered an Uptrend on October 22, 2025.
10/23/2025 - Tickeron - Stocks
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
10/22/2025 - GuruFocus
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
10/22/2025 - PR Newswire
Amylyx Pharmaceuticals (AMLX, $15.29) Aroon Indicator entered an Uptrend on October 21, 2025.
10/22/2025 - Tickeron - Stocks
Amylyx Pharmaceuticals (NASDAQ:AMLX) Shares Gap Up - Time to Buy?
10/21/2025 - MarketBeat
Steve Cohen's Point72 Buys $20M of Surging Biotech Stock That Recently Priced $125M Offering to Advance Myeloma Treatment
10/21/2025 - IB Times - Companies
Amylyx Pharmaceuticals (AMLX, $15.37) Aroon Indicator entered an Uptrend on October 20, 2025.
10/21/2025 - Tickeron - Stocks
Income Statement
Total Revenue (TTM)
-$249.00K
EBITDA (TTM)
-$196.30M
EBIT (TTM)
-$196.98M
Net Income (TTM)
-$187.60M
Balance Sheet
Total Assets (Q)
$194.60M
Total Debt (Q)
$5.96M
Total Liabilities (Q)
$26.72M
Book Value Per Share (Q)
$1.88
Cash Flow
Cash from Operations (TTM)
-$165.65M
Cash from Investing (TTM)
$83.13M
Cash from Financing (TTM)
$65.82M
Net Change in Cash (TTM)
-$16.18M
Filings
Filing Date
Thursday, August 7, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 3 and 7 (est)
Price History
Loading...
Beta
0.68
7-Day Total Return
-8.11%
30-Day Total Return
6.04%
60-Day Total Return
71.55%
90-Day Total Return
119.19%
Year to Date Total Return
259.34%
1-Year Total Return
166.60%
2-Year Total Return
-10.82%
3-Year Total Return
-60.61%
5-Year Total Return
--
52-week Low
Mar 04, 2025 - $2.60
52-week High
Oct 21, 2025 - $16.96
Valuation
Market Cap
$1.48B - Small Cap
Enterprise Value
$1.31B
Price/Sales (TTM)
-5,144.44
Price/Book (Q)
7.38
Dividends and Shares
Shares Outstanding
89.14
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
amylyx.com
Phone Number
617 682 0917
Address
43 Thorndike Street
Cambridge, MA 02141
Country
United States
Year Founded
2013
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the... more
NASDAQ 10/30/2025 4:00PM Eastern Quotes delayed